

## ESPS PEER-REVIEW REPORT

**Name of journal:** World Journal of Hepatology

**ESPS manuscript NO:** 18563

**Title:** Chronic hepatitis C: This and the new era of treatment

**Reviewer's code:** 00053580

**Reviewer's country:** Brazil

**Science editor:** Ya-Juan Ma

**Date sent for review:** 2015-04-24 17:35

**Date reviewed:** 2015-05-05 06:42

CLASSIFICATION	LANGUAGE EVALUATION	SCIENTIFIC MISCONDUCT	CONCLUSION
<input type="checkbox"/> Grade A: Excellent	<input type="checkbox"/> Grade A: Priority publishing	Google Search:	<input type="checkbox"/> Accept
<input type="checkbox"/> Grade B: Very good	<input type="checkbox"/> Grade B: Minor language polishing	<input type="checkbox"/> The same title	<input type="checkbox"/> High priority for publication
<input checked="" type="checkbox"/> Grade C: Good	<input checked="" type="checkbox"/> Grade C: A great deal of language polishing	<input type="checkbox"/> Duplicate publication	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade D: Rejected	<input checked="" type="checkbox"/> Plagiarism	<input checked="" type="checkbox"/> Minor revision
<input type="checkbox"/> Grade E: Poor		[Y] No	<input type="checkbox"/> Major revision
		BPG Search:	
		<input type="checkbox"/> The same title	
		<input type="checkbox"/> Duplicate publication	
		<input type="checkbox"/> Plagiarism	
		[Y] No	

## COMMENTS TO AUTHORS

This is a very complete review about the theme. But many language modifications should be performed before the publication

## ESPS PEER-REVIEW REPORT

**Name of journal:** World Journal of Hepatology

**ESPS manuscript NO:** 18563

**Title:** Chronic hepatitis C: This and the new era of treatment

**Reviewer's code:** 00225318

**Reviewer's country:** Spain

**Science editor:** Ya-Juan Ma

**Date sent for review:** 2015-04-24 17:35

**Date reviewed:** 2015-06-12 23:10

CLASSIFICATION	LANGUAGE EVALUATION	SCIENTIFIC MISCONDUCT	CONCLUSION
<input type="checkbox"/> Grade A: Excellent	<input type="checkbox"/> Grade A: Priority publishing	Google Search:	<input type="checkbox"/> Accept
<input type="checkbox"/> Grade B: Very good	<input type="checkbox"/> Grade B: Minor language polishing	<input type="checkbox"/> The same title	<input type="checkbox"/> High priority for publication
<input type="checkbox"/> Grade C: Good		<input type="checkbox"/> Duplicate publication	
<input checked="" type="checkbox"/> Grade D: Fair	<input checked="" type="checkbox"/> Grade C: A great deal of language polishing	<input type="checkbox"/> Plagiarism	<input checked="" type="checkbox"/> Rejection
<input type="checkbox"/> Grade E: Poor	<input type="checkbox"/> Grade D: Rejected	<input checked="" type="checkbox"/> No	<input type="checkbox"/> Minor revision
		BPG Search:	<input type="checkbox"/> Major revision
		<input type="checkbox"/> The same title	
		<input type="checkbox"/> Duplicate publication	
		<input type="checkbox"/> Plagiarism	
		<input checked="" type="checkbox"/> No	

## COMMENTS TO AUTHORS

The revision "Chronic hepatitis C: this and the new era of treatment" Bertino et al addresses an issue of great interest but present serious limitations in both form and content. This review summarizes many studies with new treatments and eventually includes the recommendations of international guidelines, basically a simple transcription of the original recommendations, both reported in other studies. It is surprising that no mention is made of the obvious difference in SVR rates in relation to the subtypes 1a and 1b as well as the existence of resistant variants to different treatments described and currently extremely interesting (Donaldson Hepatology 2015), when both factors are even included in international guidelines. and commented on recent excellent reviews (Pawlotsky Gastroenterology 2015). For example, in the section on Simeprevir is not discussed the different SVR among 1a/1b and the effect of NS3 Q80K variant, which in fact it is included in international guides (EASL guidelines 2014) and even in the own insert of the treatment itself and it has recently published a study of its prevalence in Europe (Sarrazin Antivir Res 2015 ). This report uses figures extracted from previous reports with slight modifications, including ambiguities in the color codes that make them incomprehensible (Fig 3) and even redundant as Figure 2 and Table 1.



## BAISHIDENG PUBLISHING GROUP INC

8226 Regency Drive, Pleasanton, CA 94588, USA

Telephone: +1-925-223-8242

Fax: +1-925-223-8243

E-mail: [bpgoffice@wjgnet.com](mailto:bpgoffice@wjgnet.com)

<http://www.wjgnet.com>

---

Formally gives the impression that this manuscript is a draft sent by mistake instead of the final edited version. The interline spaces are simple and jumps between paragraphs vary constantly, suggesting the involvement of different authors without an editing process to unify formats and criteria. Font size 10 is used, which I consider not useful for a manuscript, even with some changes in font (eg, page 9). Moreover, one sentence in duplicate on page 10: "NS3 / 4A protease inhibitors are drugs That inhibit the NS3 / 4A serine protease, an enzyme Involved in post-translational processing and replication of HCV. "

## ESPS PEER-REVIEW REPORT

**Name of journal:** World Journal of Hepatology

**ESPS manuscript NO:** 18563

**Title:** Chronic hepatitis C: This and the new era of treatment

**Reviewer's code:** 00070934

**Reviewer's country:** South Korea

**Science editor:** Ya-Juan Ma

**Date sent for review:** 2015-04-24 17:35

**Date reviewed:** 2015-06-17 14:10

CLASSIFICATION	LANGUAGE EVALUATION	SCIENTIFIC MISCONDUCT	CONCLUSION
<input checked="" type="checkbox"/> Grade A: Excellent	<input checked="" type="checkbox"/> Grade A: Priority publishing	Google Search:	<input checked="" type="checkbox"/> Accept
<input type="checkbox"/> Grade B: Very good	<input type="checkbox"/> Grade B: Minor language polishing	<input type="checkbox"/> The same title	<input type="checkbox"/> High priority for publication
<input type="checkbox"/> Grade C: Good	<input type="checkbox"/> Grade C: A great deal of language polishing	<input type="checkbox"/> Duplicate publication	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade D: Rejected	<input checked="" type="checkbox"/> Plagiarism	<input type="checkbox"/> Minor revision
<input type="checkbox"/> Grade E: Poor		[Y] No	<input type="checkbox"/> Major revision
		BPG Search:	
		<input type="checkbox"/> The same title	
		<input type="checkbox"/> Duplicate publication	
		<input type="checkbox"/> Plagiarism	
		[Y] No	

## COMMENTS TO AUTHORS

This review article was well summarized in HCV. Thank you for your efforts. I accept it.

## ESPS PEER-REVIEW REPORT

**Name of journal:** World Journal of Hepatology

**ESPS manuscript NO:** 18563

**Title:** Chronic hepatitis C: This and the new era of treatment

**Reviewer's code:** 01136482

**Reviewer's country:** Italy

**Science editor:** Ya-Juan Ma

**Date sent for review:** 2015-04-24 17:35

**Date reviewed:** 2015-06-18 15:09

CLASSIFICATION	LANGUAGE EVALUATION	SCIENTIFIC MISCONDUCT	CONCLUSION
<input type="checkbox"/> Grade A: Excellent	<input checked="" type="checkbox"/> Grade A: Priority publishing	Google Search:	<input type="checkbox"/> Accept
<input checked="" type="checkbox"/> Grade B: Very good	<input type="checkbox"/> Grade B: Minor language polishing	<input type="checkbox"/> The same title	<input type="checkbox"/> High priority for publication
<input type="checkbox"/> Grade C: Good	<input type="checkbox"/> Grade C: A great deal of language polishing	<input type="checkbox"/> Duplicate publication	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade D: Rejected	<input checked="" type="checkbox"/> Plagiarism	<input checked="" type="checkbox"/> Minor revision
<input type="checkbox"/> Grade E: Poor		[Y] No	<input type="checkbox"/> Major revision
		BPG Search:	
		<input type="checkbox"/> The same title	
		<input type="checkbox"/> Duplicate publication	
		<input type="checkbox"/> Plagiarism	
		[Y] No	

## COMMENTS TO AUTHORS

- Natural history section: literature clearly report the role of metabolic features, specially insulin-resistance, in the development of fibrosis in HCV patients, in particular genotype 1 and 3 are involved in this pathogenetic way (Abenavoli et al. World J Gastroenterol 2014;20:15233-40) - Many double spaces are present in the text - Please utilize only one font in the text and for figures